Szupera showed that the platelet aggregation decrease is due to the involvement of cyclooxygenases and arachidonic acid, in a similar action to that of NSAIDs, with a thromboxane A2 reduction. However, several studies indicate that the thrombocytopenia is not clinically significant since thrombopathic thrombocytopenia occurs with a platelet count below 50,000.
Szupera et al. demostraron que el mecanismo de la disminución de la agregación plaquetaria se debe al compromiso de las ciclooxigenasas y el ácido araquidónico en una acción similar a la de los antiinflamatorios no esteroideos con la disminución del tromboxano A2.